The Cellular Expression of Antiangiogenic Factors in Fetal Primate Macula

Date

Authors

Kozulin, Peter
Natoli, Riccardo
Bumsted O'Brien, Keely
Madigan, Michele C
Provis, Jan

Journal Title

Journal ISSN

Volume Title

Publisher

Association for Research in Vision and Opthalmology

Abstract

PURPOSE. To characterize the cellular expression patterns of antiangiogenic factorsdifferentially regulated in the fetal human macula. METHODS. RNA was extracted from macular, nasal, and surround biopsies of three human fetal retinas at midgestation. Relative levels of expression of pigment epithelium- derived factor (PEDF), brain natriuretic peptide (BNP), collagen type IV_2 (COL4A2), and natriuretic peptide receptors A and C (NPRA and NPRC) were determined with quantitative PCR. Cellular expression of PEDF and BNP was investigated by in situ hybridization on retinal sections from monkeys aged between fetal day 55 and 11 years. BNP, COL4A2, and NPRA proteins were localized by immunohistochemistry. Labeling was imaged and quantified by confocal microscopy and optical densitometry. RESULTS. Quantitative PCR confirmed higher levels of PEDF and BNP and lower levels of COL4A2 in the macula at midgestation. PEDF mRNA was detected in ganglion cells (GCs) and the pigment epithelium (RPE). BNP mRNA was detected in GCs and macroglia, although BNP immunoreactivity (IR) was predominantly perivascular. COL4A2-IR was detected in large blood vessels and NPRA-IR on the retinal vascular endothelium, GC axons in fetal retinas, and cone axons at all ages. Optical densitometry showed a graded expression of PEDF and BNP at all ages, with highest levels of expression in GCs in the developing fovea. CONCLUSIONS. Because the retinal vessels initially form in the GC layer, it is likely that PEDF has a key role in defining and maintaining the foveal avascular area. The precise role of BNP is unclear, but it may include both antiangiogenic and natriuretic functions.

Description

Citation

Source

Investigative Ophthalmology and Visual Science

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31